MDGL

300.15

0.00% -0.01

Handel nachbörslich: 301.01 0.86 +0.29%

Madrigal Pharmaceuticals Inc (MDGL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MDGL? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$300.16

Offen:

$299.52

24-Stunden-Volumen:

340.91K

Relative Volume:

1.07

Marktkapitalisierung:

$6.27B

Einnahmen:

Nettoeinkommen (Verlust:

$-518.67M

KGV:

-11.95

EPS:

-25.12

Netto-Cashflow:

$-438.32M

1W Leistung:

+8.11%

1M Leistung:

+10.08%

6M Leistung:

-4.34%

1J Leistung:

+10.48%

1-Tages-Spanne:

$295.43

$311.21

1-Wochen-Bereich:

$278.00

$314.22

52-Wochen-Spanne:

$200.63

$377.46

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Firmenname

Madrigal Pharmaceuticals Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

404-380-9263

Adresse

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Mitarbeiter

528

Twitter

@MadrigalPharma

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

MDGL's Discussions on Twitter

Vergleichen Sie MDGL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MDGL Madrigal Pharmaceuticals Inc	300.15	6.27B	0	-518.67M	-438.32M	-25.12
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-28	Hochstufung	B. Riley Securities	Neutral → Buy
2025-02-27	Bestätigt	H.C. Wainwright	Buy
2024-06-28	Eingeleitet	Cantor Fitzgerald	Neutral
2024-06-11	Eingeleitet	Wolfe Research	Outperform
2024-04-22	Eingeleitet	BofA Securities	Underperform
2024-03-15	Hochstufung	B. Riley Securities	Sell → Neutral
2024-03-06	Eingeleitet	Citigroup	Buy
2024-02-26	Herabstufung	B. Riley Securities	Neutral → Sell
2022-12-20	Bestätigt	Oppenheimer	Outperform
2022-12-19	Bestätigt	H.C. Wainwright	Buy
2022-12-19	Bestätigt	Piper Sandler	Overweight
2022-12-19	Hochstufung	Raymond James	Underperform → Mkt Perform
2022-07-08	Herabstufung	B. Riley Securities	Buy → Neutral
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Fortgesetzt	Goldman	Buy
2020-11-24	Fortgesetzt	Evercore ISI	Outperform
2020-11-06	Bestätigt	H.C. Wainwright	Buy
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-06-05	Eingeleitet	BMO Capital Markets	Market Perform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-01-30	Eingeleitet	Canaccord Genuity	Buy
2020-01-09	Hochstufung	UBS	Neutral → Buy
2019-11-07	Bestätigt	H.C. Wainwright	Buy
2019-06-25	Eingeleitet	Stifel	Hold
2019-06-10	Hochstufung	B. Riley FBR	Neutral → Buy
2019-02-28	Bestätigt	H.C. Wainwright	Buy
2019-02-22	Eingeleitet	SVB Leerink	Outperform
2019-01-23	Eingeleitet	UBS	Neutral
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-12-12	Eingeleitet	B. Riley FBR	Neutral
2018-11-19	Herabstufung	Raymond James	Mkt Perform → Underperform
2018-11-16	Hochstufung	Evercore ISI	In-line → Outperform
2018-09-04	Eingeleitet	Citigroup	Buy
2018-08-06	Herabstufung	Goldman	Buy → Neutral
2018-06-28	Eingeleitet	Raymond James	Mkt Perform

Alle ansehen

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

Jun 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News - GuruFocus

Jun 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 17, 2025

Jun 16, 2025

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others - insights.citeline.com

Jun 16, 2025

Jun 15, 2025

(MDGL) Investment Analysis - news.stocktradersdaily.com

Jun 15, 2025

Jun 13, 2025

Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference - MSN

Jun 13, 2025

Jun 11, 2025

Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025

Cantor Fitzgerald Predicts MDGL FY2026 Earnings - Defense World

Jun 11, 2025

Jun 10, 2025

Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 10, 2025

Jun 09, 2025

Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 09, 2025

Jun 06, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Jun 06, 2025

Jun 03, 2025

(MDGL) On The My Stocks Page - news.stocktradersdaily.com

Jun 03, 2025

Jun 02, 2025

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewswire

Jun 02, 2025

May 29, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Ameriprise Financial Inc. - Defense World

May 29, 2025

May 28, 2025

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com

May 28, 2025

May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com

May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK

May 26, 2025

May 25, 2025

Cetera Investment Advisers Has $889,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World

May 25, 2025

May 23, 2025

When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com

May 23, 2025

May 17, 2025

In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha

May 17, 2025

May 16, 2025

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma - insights.citeline.com

May 16, 2025

May 15, 2025

Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN

May 13, 2025

May 11, 2025

Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN

May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus

May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus

May 11, 2025

May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times

May 10, 2025

Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com

May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.

May 10, 2025

May 08, 2025